Novartis AG (NYSE:NVS – Get Rating) – Stock analysts at Jefferies Financial Group issued their Q1 2022 earnings per share estimates for Novartis in a research note issued on Tuesday, April 19th. Jefferies Financial Group analyst P. Welford anticipates that the company will post earnings per share of $1.41 for the quarter. Jefferies Financial Group also issued estimates for Novartis’ Q2 2022 earnings at $1.46 EPS, Q3 2022 earnings at $1.58 EPS, Q4 2022 earnings at $1.60 EPS, FY2022 earnings at $6.05 EPS, FY2023 earnings at $6.79 EPS, FY2024 earnings at $7.06 EPS, FY2025 earnings at $7.37 EPS and FY2026 earnings at $7.83 EPS.
NVS has been the subject of several other reports. Barclays upped their price target on shares of Novartis from CHF 80 to CHF 85 in a research report on Thursday, April 14th. Citigroup initiated coverage on shares of Novartis in a report on Monday, January 10th. They issued a “buy” rating on the stock. Erste Group raised shares of Novartis from a “hold” rating to a “buy” rating in a research note on Thursday, April 14th. Stifel Nicolaus initiated coverage on Novartis in a research note on Monday, February 28th. They issued a “hold” rating on the stock. Finally, Societe Generale reduced their price target on Novartis from CHF 107 to CHF 105 in a report on Thursday, February 3rd. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $89.33.
Novartis (NYSE:NVS – Get Rating) last posted its quarterly earnings results on Wednesday, February 2nd. The company reported $1.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.44 by ($0.04). Novartis had a net margin of 46.27% and a return on equity of 24.57%. The business had revenue of $13.23 billion for the quarter, compared to analysts’ expectations of $13.25 billion. During the same quarter in the previous year, the company earned $1.34 earnings per share. The business’s quarterly revenue was up 3.6% on a year-over-year basis.
The business also recently announced an annual dividend, which was paid on Thursday, March 17th. Stockholders of record on Wednesday, March 9th were given a $1.175 dividend. The ex-dividend date of this dividend was Tuesday, March 8th. This represents a dividend yield of 1.36%. Novartis’s dividend payout ratio is 20.28%.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Fisher Asset Management LLC boosted its position in shares of Novartis by 0.8% during the fourth quarter. Fisher Asset Management LLC now owns 10,384,666 shares of the company’s stock valued at $908,347,000 after purchasing an additional 79,637 shares in the last quarter. Boston Partners boosted its position in shares of Novartis by 6.7% during the fourth quarter. Boston Partners now owns 4,677,403 shares of the company’s stock valued at $409,194,000 after purchasing an additional 292,854 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Novartis by 21.5% during the third quarter. Wellington Management Group LLP now owns 4,214,932 shares of the company’s stock valued at $344,696,000 after purchasing an additional 745,157 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Novartis by 2.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 4,205,694 shares of the company’s stock valued at $367,871,000 after purchasing an additional 89,226 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Novartis by 35.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,870,136 shares of the company’s stock worth $338,521,000 after purchasing an additional 1,003,235 shares during the period. Institutional investors own 9.72% of the company’s stock.
Novartis Company Profile (Get Rating)
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.
- Get a free copy of the StockNews.com research report on Novartis (NVS)
- 3 Analyst Favorite Blue-Chip Stocks to Buy Now
- Does PNC Financial Stock Belong in Your Portfolio?
- Institutional Buying Puts A Bottom In Manpower Group Inc
- Workhorse Johnson & Johnson Plows New All-Time Highs
- Fastenal Stock is Ready to Sprint Higher
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.